Share on StockTwits

Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost acquired 20,500 shares of the stock in a transaction dated Tuesday, June 10th. The shares were purchased at an average cost of $9.16 per share, for a total transaction of $187,780.00. Following the completion of the purchase, the chief executive officer now directly owns 1,987,500 shares of the company’s stock, valued at approximately $18,205,500. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Several analysts have recently commented on the stock. Analysts at TheStreet upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. Finally, analysts at Oppenheimer cut their price target on shares of Opko Health from $13.00 to $12.00 in a research note on Monday, May 12th. They now have an “outperform” rating on the stock. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Opko Health presently has a consensus rating of “Buy” and an average target price of $12.50.

Shares of Opko Health (NYSE:OPK) traded down 0.54% during mid-day trading on Wednesday, hitting $9.16. 765,611 shares of the company’s stock traded hands. Opko Health has a 52-week low of $6.60 and a 52-week high of $12.95. The stock’s 50-day moving average is $8.48 and its 200-day moving average is $8.88. The company’s market cap is $3.790 billion.

Opko Health (NYSE:OPK) last released its earnings data on Friday, May 9th. The company reported ($0.11) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.10) by $0.01. The company had revenue of $22.30 million for the quarter, compared to the consensus estimate of $22.77 million. On average, analysts predict that Opko Health will post $-0.38 earnings per share for the current fiscal year.

OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.